| 1 |
Tan S, Yang Y, Yang W, Han Y, Huang L, Yang R, Hu Z, Tao Y, Liu L, Li Y, Oyang L, Lin J, Peng Q, Jiang X, Xu X, Xia L, Peng M, Wu N, Tang Y, Cao D, Liao Q, Zhou Y. Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment. J Exp Clin Cancer Res 2023;42:59. [PMID: 36899389 DOI: 10.1186/s13046-023-02634-z] [Reference Citation Analysis]
|
| 2 |
Kang Y, Li S. Nanomaterials: Breaking through the bottleneck of tumor immunotherapy. Int J Biol Macromol 2023;230:123159. [PMID: 36610572 DOI: 10.1016/j.ijbiomac.2023.123159] [Reference Citation Analysis]
|
| 3 |
Zhao Z, Fang L, Lv D, Chen L, Zhang B, Wu D. Design and synthesis of Ag NPs/chitosan-starch nano-biocomposite as a modern anti-human malignant melanoma drug. Int J Biol Macromol 2023;236:123823. [PMID: 36842739 DOI: 10.1016/j.ijbiomac.2023.123823] [Reference Citation Analysis]
|
| 4 |
Wang X, Huang R, Wu W, Xiong J, Wen Q, Zeng Y, Chen T, Li J, Zhang C, Zhong JF, Yang S, Zhang X. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia. Acta Biomater 2023;157:381-94. [PMID: 36375786 DOI: 10.1016/j.actbio.2022.11.007] [Reference Citation Analysis]
|
| 5 |
Siminzar P, Tohidkia MR, Eppard E, Vahidfar N, Tarighatnia A, Aghanejad A. Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment. Mol Imaging Biol 2022. [DOI: 10.1007/s11307-022-01795-1] [Reference Citation Analysis]
|
| 6 |
Wang D, Cui Q, Yang YJ, Liu AQ, Zhang G, Yu JC. Application of dendritic cells in tumor immunotherapy and progress in the mechanism of anti-tumor effect of Astragalus polysaccharide (APS) modulating dendritic cells: a review. Biomed Pharmacother 2022;:113541. [PMID: 36127221 DOI: 10.1016/j.biopha.2022.113541] [Reference Citation Analysis]
|
| 7 |
Mukherjee AG, Wanjari UR, Namachivayam A, Murali R, Prabakaran DS, Ganesan R, Renu K, Dey A, Vellingiri B, Ramanathan G, Doss C. GP, Gopalakrishnan AV. Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. Vaccines 2022;10:1493. [DOI: 10.3390/vaccines10091493] [Reference Citation Analysis]
|
| 8 |
Hartmann L, Osen W, Eichmüller OL, Kordaß T, Furkel J, Dickes E, Reid C, Debus J, Brons S, Abdollahi A, Moustafa M, Rieken S, Eichmüller SB. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215928] [Reference Citation Analysis]
|
| 9 |
Ghaderi SS, Riazi-Rad F, Qamsari ES, Bagheri S, Rahimi-Jamnani F, Sharifzadeh Z. Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. BMC Biotechnol 2022;22:22. [PMID: 35996120 DOI: 10.1186/s12896-022-00752-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Lou X, Zhao K, Xu J, Shuai L, Niu H, Cao Z, Wang J, Zhang Y. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment. Front Immunol 2022;13:950213. [DOI: 10.3389/fimmu.2022.950213] [Reference Citation Analysis]
|
| 11 |
Xu G, Luo Y, Wang H, Wang Y, Liu B, Wei J. Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Lett 2022;:215699. [PMID: 35487312 DOI: 10.1016/j.canlet.2022.215699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
